INTERNATIONAL PATENT: JANSSEN BIOTECH, INC FILES APPLICATION FOR "TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D AND CD3 FOR THE TREATMENT OF MULTIPLE MYELOMA"

GENEVA, July 2 -- JANSSEN BIOTECH, INC (800/850 Ridgeview DriveHorsham, Pennsylvania 19044) filed a patent application (PCT/IB2024/063022) for "TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D AND CD3 FOR THE TREATMENT OF MULTIPLE MYELOMA" on Dec 20, 2024. With publication no. WO/2025/134050, the details related to the patent application was published on Jun 26, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): LEE, Sangmin (c/o Janssen Research & Development, LLC, 920 US Route 202, PO Box 300Raritan, New Jersey 08869), GOLDBERG, Jenna (c/o Janssen Research & Development, LLC, 920 US Route 202, PO ...